| zoledronic acid / Generic mfg. |
ACTRN12615001048572: Zoledronic acid to improve low bone mineral density in non-ambulatory adults with cerebral palsy |
|
|
| Not yet recruiting | 4 | 40 | | | Anne Trinh | cerebral palsy, osteoporosis | | | | |
ACTRN12611000507987: A randomised, double-blind, one-year controlled trial comparing Aclasta (zoledronic acid) 5 mg intravenously (i/v) against placebo infusion in patients with anti-epileptic (AED) drug induced bone loss |
|
|
| Not yet recruiting | 4 | 60 | | | Melbourne Health, Novartis Pharmaceuticals Australia Pty Limited | Bone loss (osteoporosis), Use of anti-epileptic drugs | | | | |
ACTRN12624001403527: A pragmatic, randomised study of treatments to prevent the acute phase response following first zoledronate infusion |
|
|
| Not yet recruiting | 4 | 180 | | | University of Auckland, HRC (Health Research Council) of NZ | Osteoporosis | | | | |
ChiCTR2000037044: Multicenter clinical study on standardized diagnosis and treatment of thyroid cancer spinal metastasis |
|
|
| Recruiting | 4 | 80 | | PD-1 monoclonal antibody combined with zoledronic acid and denosumab ;PD-1 monoclonal antibody combined with zoledronic acid | Affiliated Sixth People's Hospital, Shanghai Jiaotong University; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, funding | Thyroid cancer bone metastasis | | | | |
| Completed | 4 | 50 | | | Professor I Reid, Health Research Council of New Zealand | Post menopausal Osteopenia | | | | |
ACTRN12609000593235: Efficacy of Zoledronate in fracture prevention in osteopenic postmenopausal women. |
|
|
| Active, not recruiting | 4 | 2000 | | | Professor Ian Reid, The Health Research Council of New Zealand | Fractures in women with Postmenopausal osteopenia | | | | |
2011-003154-12: Investigation of the effect of Zoledronic acid on circulating tumor cells in the blood in men with hormone refractory metastatic prostate cancer. |
|
|
| Ongoing | 4 | 60 | Europe | Solvent for solution for infusion, Zometa | Privatärztliche urologische Partnerschaft GbR, EuromedClinic, Novartis | hormone refractory metastatic prostate cancer, prostate cancer, metastatic, hormones are no further effective, Diseases [C] - Cancer [C04] | | | | |
2011-005327-41: Study of the analgesic efficacy of the association zoledronic acid and 153Sm-lexidronam in patients with skeletal metastases from prostatic cancer Studio dell'efficacia analgesica dell'associazione acido zoledronico e 153Sm-lexidronam in pazienti con metastasi ossee da tumore della prostata |
|
|
| Ongoing | 4 | 44 | Europe | Powder and solvent for solution for infusion, Solution for injection, ZOMETA*IV 1FL 4MG+1F 5ML SOLV, QUADRAMET*EV 1F 1,3GBQ/ML | ISTITUTO NAZIONALE PER LA CURA TUMORI, Fondazione IRCCS Istituto Nzionale dei Tumori | Population enrolled in the study is represented by patients bearing advanced prostatic cancer with skeletal metastases and bone pain cancer-associated and treated with analgesic drugs La popolazione in studio è rappresentata da pazienti con dolore osseo da cancro della prostata in fase avanzata con presenza accertata di metastasi ossee e in trattamento con farmaci analgesici., Patients with advanced prostatic cancer and bone pain associated to the skeletal lesions Pazienti con cancro della prostata in stadio avanzato e dolore associato alle metastasi ossee, Diseases [C] - Cancer [C04] | | | | |
| Completed | 4 | 1050 | | | Dr Mark Bolland, Health Research Council of New Zealand | Osteoporosis | | | | |
ChiCTR-PRC-13003088: Clinical study of zoledronic acid injection used to prevent early bone loss after total hip arthroplasty |
|
|
| Completed | 4 | 120 | | zoledronic acid injection ;No zoledronic acid injection | The First Affiliated Hospital of Guangzhou University of Chinese Medicine; The First Affiliated Hospital of Guangzhou University of Chinese Medicine, self-prepare capital | bone loss | | | | |
ChiCTR-TRC-09000408: A clinical study of the effects of Zoledronic Acid in the prevention of metastasis of breast cancer to bone, and impact for disease process of breast cancer patients |
|
|
| Completed | 4 | 240 | | Additional to the basal chemotherapy, Zoledronic Acid 4mg/time, intravenous drip, 3~4 weeks once, after three times changed to three months once, total six times ;Basal chemotherapy same as group A without Zoledronic Acid | West China Hospital, Sichuan University; Beijing Novartis Pharma Co., Ltd, Beijing Novartis Pharma Co.,Ltd | Breast cancer | | | | |
ChiCTR-TNC-10000899: The Relationship of The Change of NTX And Outcomes in Patients With Bone Metastatic Breast Cancer |
|
|
| Recruiting | 4 | 334 | | zoledronic acid 4mg Q3-5weeks | West China Hospital of Sichuan University; Level of the institution：, Self-funding | bone metastases in breast cancer | | | | |
2004-004223-36: Short term biological study effects of Zoledronate and Letrozole on invasive breast cancer |
|
|
| Ongoing | 4 | 110 | Europe | Letrozole, Zoledronic Acid, Femara, Zometa, Femara, Zometa | South Manchester University Hospital | Breast Cancer | | | | |
2005-004765-42: An Open label Randomised, multicentre study to evaluate the efficacy of two Zometa (Zoledronic acid) schedules on bone mineral density in prostrate cancer patients undergoing Androgen deprivation Therapy (ADT) |
|
|
| Ongoing | 4 | 300 | Europe | Zometa 4mg/5ml concentrate for solution for infusion, ZOL446, ZOMETA, ZOMETA | Novartis Pharmaceuticals UK Ltd | Decreased bone mineral density in prostate cancer patients being treated with ADT | | | | |
2008-005405-20: Bisfosfonaattien vaikutus luuntiheyteen ja luun uusiutumiseen leikkauksen jälkeen primaarissa hyperparatyreoosissa. |
|
|
| Ongoing | 4 | 80 | Europe | Aclasta, Aclasta | Department of Medicine, Helsinki University Central Hospital | Potilailla on primaari hyperparatyreoosi ja osteoporoosi. Hyperparatyreoosin hoidoksi on suunniteltu leikkaushoitoa. | | | | |
2007-005647-14: Gamma Delta T Cells and their role in the acute phase reaction to intravenous bisphosphonates |
|
|
| Ongoing | 4 | 120 | Europe | Bonviva, Aclasta, Bonviva, Aclasta | Cardiff University | Patients with osteoporosis or Paget\'s disease of bone | | | | |
2010-022318-22: Tsoledronaatti hoito paikallista kiihtynyttä luunvaihdunta- oireyhtymää sairastavilla potilailla |
|
|
| Ongoing | 4 | 146 | Europe | Zometa 4mg ja Aclasta 5mg (vaikuttava aine tsoledronaatti), Zometa 4mg ja Aclasta 5mg (vaikuttava aine tsoledronaatti) | Maarit Valkealahti / University hospital of Oulu | Tässä tutkimuksessa esitetään bisfosfonaatti –lääkkeen käyttöä uusissa indikaatioissa. Haemme tällä tutkimussuunnitelmalla lupaa kliiniseen tutkimukseen, jossa selvitetään, mikä on lääkkeen teho hoidettaessa paikallisesti kiihtynyttä luunvaihduntaoireyhtymää (FHBT, focal high bone turn over) näistä potilaista omana ryhmänä seuraamme reisiluunpään osteonekroosia sairastavia potilaita (FHBT-FH focal high bone turn over- in the femoral head). | | | | |
2009-017369-47: An in-vitro observational pilot study of the role of gamma delta T cells in the acute phase reaction to intravenous bisphosphonate; in blood samples donated by patients receiving intravenous bisphosphonate treatment for Paget’s disease or Osteoporosis final Version 1.6 |
|
|
| Ongoing | 4 | 20 | Europe | Zoledronate (Aclasta), | Research and Development Office Cardiff and Vale NHS Trust | Osteoporosis and Paget\'s disease | | | | |
2010-023193-39: \"Ensayo clínico aleatorizado, doble ciego, de grupos paralelos, controlado con placebo para la valoración de la eficacia del zoledronato endovenoso para disminución de la resorción periprotésica en pacientes con protésis total de rodilla\". |
|
|
| Ongoing | 4 | 60 | Europe | ACLASTA 5 mg solución para perfusión, ACLASTA 5 mg solución para perfusión | Fundación Institut de Recerca de l\'Hospital de la Sta Creu i Sant Pau | La disminución de la masa ósea periprotésica, que determina las propiedades mecánicas del hueso alrededor del implante. | | | | |
2010-019656-41: Effects of Zoledronic acid on making blood vessels stiff in women by comparing twins, where one is taking the medicine and the other is taking a placebo |
|
|
| Ongoing | 4 | 220 | Europe | Aclasta® 5 mg solution for infusion, Aclasta® 5 mg solution for infusion | King’s College London, Guy’s and St Thomas’ NHS Foundation Trust, NIHR ARTISTIC programme award to artherosclerosis theme | Arterial stiffness and arterial calcification | | | | |
2011-000291-34: Direct effect of four different compounds on experimental pain |
|
|
| Ongoing | 4 | 48 | Europe | Adenoscan, zoledronic acid, Calcitonine-Sandoz, dexamethasone, na, | | experimental pain | | | | |
2013-003359-39: Treatment with Zoledronic acid or Tenofovir Switching in HIV-Infected Tratamiento con ácido zoledrónico vs sustitución de tenofovir en pacientes infectados por el VIH |
|
|
| Ongoing | 4 | 28 | Europe | Aclasta, Aclasta | Fundació Clínic per a la Recerca Biomèdica, St. Vicent's Hospital | low bone mineral density - HIV Baja densidad mineral ósea - VIH | | | | |
| Ongoing | 4 | 170 | Europe | Zoledron acid, Zoledronic Acid, Zoledronic Acid | Odense University Hostital, Odense University Hospital, Nordic Myeloma Study Group | Multiple Myeloma. | | | | |
ChiCTR-ONRC-13004145: Evaluation the role of zolendronic acid in the treatment of patents with initial daignosed bone metastatic prostate cancer |
|
|
| Recruiting | 4 | 100 | | Zoledronic acid+MAB ;Zoledronic acid+MAB | West China Hospital, SiChuan University; Level of the institution：, Reseach article grant of SiChuan University | bone metastatic prostate cancer | | | | |
2009-009134-32: Bristol Randomised Controlled Trial of Zoledronic Acid in Malignant Pleural disease(Pilot Study). |
|
|
| Ongoing | 4 | 30 | Europe | Zometa 4mg/5ml concentration for solution for infusion, Zometa 4mg/5ml Concentrate for Solution for Infusion., Zometa 4mg/5ml Concentrate for Solution for Infusion. | North Bristol NHS Trust | Malignant pleural disease of all histological cell types. 50% patients in trial will have indwelling pleural catheters for management of breathlessness. | | | | |
2015-004433-26: Zoledronic acid in the management of Mesothelioma - a feasibility trial |
|
|
| Ongoing | 4 | 70 | Europe | Zoledronic acid, Concentrate for solution for injection, Zometa 4 mg/5 ml concentrate for solution for infusion | North Bristol NHS Trust, NIHR - RfPB funding | Malignant pleural mesothelioma, Cancer of the lung lining, usually as a consequence of previous asbestos exposure., Diseases [C] - Cancer [C04] | | | | |
2016-000852-91: Study to investigate changes in BMD of the lumbar spine (LS) one year after treatment discontinuation in denosumab-treated women and in denosumab-treated women who received a single infusion of zoledronic acid after treatment discontinuation. |
|
|
| Ongoing | 4 | 80 | Europe | Solution for infusion, Aclasta | Leiden University Medical Center, Leiden University Medical Center | Treatment of patients with with postmenopausal osteoporosis, Diseases of bones that leads to an increased risk of fracture, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2014-004318-27: Intravenous bisphosphonate in stress fracture treatment Intravenøs bisfosfonat ved stressbrudd |
|
|
| Not yet recruiting | 4 | 40 | Europe | Aclasta / zoledronic acid, Injection, Aclasta | Oslo University Hospital, Oslo University Hospital | Stress fractures in the foot Stressfrakturer i foten, Stress fractures in the foot Stressbrudd i foten, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
ChiCTR1900021796: In vivo effects of zoledronic acid on lymphocyte subpopulations in patients with primary osteoporosis |
|
|
| Recruiting | 4 | 60 | | zoledronic acid | Jinan Central Hospital affiliated to Shandong University; Jinan Central Hospital affiliated to Shandong University, Phd FUND | primary osteoporosis | | | | |
2019-001650-26: Zoledronic acid for prevention of bone loss after bariatric surgery Zoledronsyre til forebyggelse af knogletab efter operation for overvægt |
|
|
| Ongoing | 4 | 70 | Europe | Solution for infusion, Aclasta | Hospital South West Jutland, Hospital South West Jutland | Morbid obese subjects undergoing bariatric surgery, Morbid obese subjects undergoing bariatric surgery, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
ChiCTR1900021323: Exploration of individualized drug interval for zoledronic acid in the treatment of primary osteoporosis |
|
|
| Recruiting | 4 | 80 | | Zoledronic acid ; Zoledronic acid | Department of Endocrinology and Metabolism, West China Hospital, Sichuan University; West China Hospital, Sichuan University, Sichuan Provincial Cadre Health Research Fund | Primary osteoporosis | | | | |
ChiCTR-IPR-17010456: Apatinib and radiotherapy Compared with zoledronic acid and radiotherapy Treatment in Patients With bone metastases of Malignant tumor |
|
|
| Recruiting | 4 | 60 | | Apatinib, 250 mg po, qd, Local radiotherapy ;zoledronic acid: 4 mg, iv, Every 4 weeks; Local radiotherapy | Da Hospital; Da Hospital, self-financing | cancer | | | | |
NCT03932071: Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma |
|
|
| Recruiting | 4 | 150 | RoW | Zoledronic Acid | Second Affiliated Hospital, School of Medicine, Zhejiang University | Lung Metastases, Tumor Necrosis | 01/20 | 01/23 | | |
REaCT-ZOL, NCT03664687: Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer |
|
|
| Active, not recruiting | 4 | 211 | Canada | Zoledronate, Zoledronic acid | Ottawa Hospital Research Institute | Early-stage Breast Cancer | 04/20 | 12/24 | | |
ChiCTR1800016845: Thalidomide in the treatment of bone metastases with moderate anemia: a prospective, randomized controlled clinical trial |
|
|
| Recruiting | 4 | 280 | | Thalidomide+zoledronic acid ;zoledronic acid | Affiliated Sixth People's Hospital, Shanghai Jiaotong University; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Self-financing | advanced malignant tumors | | | | |
2020-000638-17: Zoledronate early to patients after hip surgery-safe and effective? |
|
|
| Not yet recruiting | 4 | 300 | Europe | Zoledronic Acid, M05B A08, Infusion, Aclasta | Oslo University Hospital, Oslo University Hospital | Osteoporosis, Osteoporosis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
ChiCTR-IPR-16008568: A clinical trial for zoledronic acid added into new adjuvant chemotherapy on osteosarcoma patients |
|
|
| Recruiting | 4 | 150 | | zoledronate ;placebo | 2nd affiliated hospital of ZheJiang University; 2nd Affiliated Hospital, ZheJiang University, raise independently | osteosarcoma | | | | |
ChiCTR1800015367: The Clinical Outcome Study for Osteoporotic Patients Using Bisphosphonate |
|
|
| Not yet recruiting | 4 | 5088 | | Ca 600mg/d + 1aOH-VitD 0.5ug/d ;Zoledronate 5mg/y, VD.+Ca600mg/d+1aOHvitD 0.5ug/d ;Ca 600mg/d + 1aOH-VitD 0.5ug/d ;Aln70mg/w+Ca600mg/d+1aOHvitD0.5ug/d | Shanghai Tongji Hospital; Level of the institution：, The Key Program of Clinical Research Initiating Fund of Shanghai Tongji Hospital | osteoporosis | | | | |
2019-004766-17: Effects of zoledronic acid after a fragility fracture Zoledronate till patienter med fraktur-En randomiserad dubbel-blind studie |
|
|
| Not yet recruiting | 4 | 2900 | Europe | Infusion, Aclasta 5 mg solution for infusion | Region Uppsala, Swedish Research Council | Non-hip, non-vertebral fragility fracture Fragilitetsfraktur annat än kotfraktur eller höftfraktur, Fracture other than of the hip or spine that occurs after a fall from standing height or less Fraktur (exklusive fraktur i rygg eller höft) som orsakas av ett fall från ståhöjd eller lägre, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
NCT02480634: Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | 4 | 280 | NA | Zoledronic acid, Zometa, Radiotherapy | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Non-small Cell Lung Cancer, Bone Metastasis | 09/21 | 12/22 | | |
ChiCTR2000034692: Clinical observation of zoledronic acid injection in the treatment of primary osteoporosis and osteoporotic fracture |
|
|
| Recruiting | 4 | 80 | | Zoledronic acid injection | Chizhou People's Hospital; Chizhou People's Hospital, Sichuan Kelun Pharmaceutical Co., Ltd | Primary osteoporosis 、Osteoporotic fracture | | | | |
NCT04719481: Pravastatin Reduces Acute Phase Response of Zoledronic Acid |
|
|
| Not yet recruiting | 4 | 110 | NA | Pravastatin Sodium 80 MG, Meibailezhen, Placebo, Meibailezhen placebo | Peking University Third Hospital | Postmenopausal Osteoporosis | 11/21 | 04/22 | | |
| Not yet recruiting | 4 | 80 | NA | Zoledronic Acid, Placebo | Karolinska Institutet | Seropositive Muskuloskeletal Complaints | 12/21 | 12/22 | | |
ACTRN12621000415808: A randomized study investigating whether taking a steroid medication (dexamethasone) for three days reduces the risk of an acute phase response reaction |
|
|
| Completed | 4 | 60 | | | Bone & Joint Research Group, University of Auckland , Health Research Council of New Zealand | osteoporosis
, Paget's disease | | | | |
ChiCTR1800017906: The effect of zoledronic acid on bone turnover and metabolic disorder in patients with osteoporosis with type 2 diabetes mellitus |
|
|
| Not yet recruiting | 4 | 120 | | zoledronic acid injection ;caltrate D | Ninth People 's Hospital, Affiliated to Shanghai Jiaotong University, School of Medicine; Ninth People 's Hospital, Affiliated to Shanghai Jiaotong University, School of Medicine, Clinical research funding of Ninth People 's Hospital, Affiliated to Shanghai Jiaotong University, School of Medicine | osteoporosis and Type 2 diabetes | | | | |
ChiCTR2100051421: Zoledronic acid effect on bone mineral density and function at 1 year after screw fixation for osteoporotic vertebral compression fractures: a parallel double-blind randomized controlled clinical trial |
|
|
| Not yet recruiting | 4 | 80 | | zoledronate ;placebo | Shenzhen People's Hospital; Shenzhen People's Hospital, Basic research key project of Shenzhen Science and Technology Innovation Commission | osteoporotic vertebral compression fractures | | | | |
ChiCTR2100051424: Internal screw fixation of dissulzumab vs zoledronic acid and osteoporotic vertebral compression fractures |
|
|
| Not yet recruiting | 4 | 80 | | denosumab+placebo ;denosumab placebo+zoledronic acid | Shenzhen People's Hospital; Shenzhen People's Hospital, Basic research key project of Shenzhen Science and Technology Innovation Commission | osteoporotic vertebral compression fractures | | | | |
| Active, not recruiting | 4 | 350 | Europe | Teriparatide Pen Injector, Forsteo, Forteo, Zoledronic Acid, Aclasta 5mg solution for infusion, Zoledronic acid 5mg/100ml solution for infusion | University of Edinburgh, NHS Lothian | Osteogenesis Imperfecta | 02/25 | 07/25 | | |
| Completed | 4 | 101 | RoW | Zoledronic Acid, Aclasta, Denosumab, Prolia | National Taiwan University Hospital | Osteoporosis | 07/23 | 12/23 | | |
| Completed | 4 | 158 | Europe | Zoledronic acid, Zometa | Thomas Lund | Multiple Myeloma | 02/23 | 02/23 | | |
2023-000007-39: Bisphosphonate vs. Placebo Prior to Parathyroidectomy in Primary Hyperparathyroidisme: A Randomized, blinded Placebo-controlled Trial |
|
|
| Ongoing | 4 | 200 | Europe | Solution for injection/infusion, Zoledronic acid | Aarhus University Hospital, Department of Endocrinology and Internal Medicine, Department of Endocrinology and Internal Medicine | Osteopenia i.e. bone mineral density T-score < -1 in patients with primary hyperparathyroidism, Low bone mass, Body processes [G] - Bones and nerves physological processes [G11] | | | | |
| Enrolling by invitation | 4 | 40 | Europe | Denosumab 60 MG/ML Prefilled Syringe [Prolia], Xgeva, Zoledronic Acid, Aclasta | University Medical Centre Ljubljana | Primary Hyperparathyroidism, Osteoporosis | 05/23 | 05/23 | | |
| Completed | 4 | 201 | US | denosumab, Prolia, Placebo, Calcium and Vitamin D | Susan L. Greenspan, National Institutes of Health (NIH), National Institute on Aging (NIA) | Osteoporosis, Postmenopausal, Osteoporosis, Osteoporotic Fractures | 08/23 | 08/23 | | |
ZOOM, NCT05361408: A Clinical Trial to Evaluate Efficacy of Once or Twice ZOledronic Acid After Different Duration of denOsumMab Administration in Postmenopausal Women With Osteoporosis ( Study) |
|
|
| Recruiting | 4 | 114 | RoW | Zoledronic acid, once, Zoledronate, Zoledronic acid, twice | Yonsei University | Osteoporosis | 09/23 | 09/23 | | |
NCT04597931: Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density |
|
|
| Not yet recruiting | 4 | 30 | NA | Romosozumab, Zoledronic Acid | Sheba Medical Center | Osteoporosis Fracture, Spinal Cord Injuries | 11/23 | 11/23 | | |
NCT06135298: FARE Augmentation of Proximal Femoral Fractures with CaS/HA and Systemic ZA |
|
|
| Recruiting | 4 | 20 | RoW | OSTEOSYNTHESIS, Proximal femoral nail with helical blade, Zoledronic acid, Ronidro 5mg/Bag 100 mL Inj, CERAMENT BONE VOID FILLER (BVF), CaS/HA | Aksaray University, Lund University Hospital | Trochanteric Fracture of Femur, Osteoporotic Fracture of Femur, Hip Fractures, Bone Density, Low | 07/25 | 12/25 | | |
NCT06051344: Effect of Zoledronic Acid in Primary Knee Osteoarthritis |
|
|
| Recruiting | 4 | 92 | RoW | Zoledronic acid | Toufiqe-E-Ealahi | Primary Osteoarthritis | 12/23 | 12/23 | | |
ChiCTR2100045485: Comparative study of zoledronic acid and alendronate in the treatment of postmenopausal osteoporosis |
|
|
| Recruiting | 4 | 400 | | Alendronate 70mg/week orally ;Zoledronic acid 5mg/year intravenously | The First Affiliated Hospital of Xi 'an Jiaotong University; The First Affiliated Hospital of Xi 'an Jiaotong University, Academic community support | Postmenopausal osteoporosis | | | | |
NCT04087096: Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery |
|
|
| Active, not recruiting | 4 | 36 | US | Denosumab, Prolia, Placebo, Zoledronic Acid, Reclast | Massachusetts General Hospital, University of California, San Francisco, San Francisco VA Health Care System | Bariatric Surgery Candidate, Bone Loss | 08/24 | 08/24 | | |
ChiCTR2200063438: A multicenter clinical study on the efficacy and safety of Denosumab in the treatment of myeloma bone disease |
|
|
| Not yet recruiting | 4 | 120 | | Denosumab ;Zoledronic acid ;Denosumab | Tianjin Medical University General Hospital; Blood Diseases Hospital and Institute of Hematology, PUMC, Tianjin Medical University General Hospital | Multiple Myeloma | | | | |
NCT04719650: Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid |
|
|
| Not yet recruiting | 4 | 64 | NA | Zoledronic Acid Injection, Yigu, Placebo, Yigu Placebo | Peking University Third Hospital | Postmenopausal Osteoporosis | 10/24 | 11/24 | | |
REaCT-HOLD BMA, NCT04549207: Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer |
|
|
| Active, not recruiting | 4 | 240 | Canada | Bone modifying agent, Zoledronate, Denosumab, Pamidronate | Ottawa Hospital Research Institute | Breast Cancer, Castration-resistant Prostate Cancer | 06/25 | 06/26 | | |
NCT06762730: Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals |
|
|
| Recruiting | 4 | 110 | RoW | Zoledronic Acid 5 mg/Bag 100 ml Inj | Hadassah Medical Organization, Sheba Medical Center, Rambam Hospital, Haifa, Israel | HIV Infected Individuals, Osteopenia | 12/28 | 12/32 | | |
| Recruiting | 4 | 200 | Europe | Zoledronate, Placebo | Aarhus University Hospital | Osteoporosis, Postmenopausal | 02/25 | 02/27 | | |
SAFEST, NCT06767150: StrAtegies for Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal OSTeoporosis |
|
|
| Not yet recruiting | 4 | 200 | Europe | a second infusion of ZOL when crosslaps levels reach 300 pg/mL, a rescue second infusion at month-12 (standard traitment) | University Hospital, Toulouse | Postmenopausal Osteoporosis | 03/30 | 03/30 | | |
Zoo-P, NCT05743179: The Effect of Zoledronate on the Prevention of Pneumonia in Hip Fracture Patients |
|
|
| Recruiting | 4 | 2692 | RoW | Zoledronate, Zoledronic acid, Aclasta | The University of Hong Kong, Queen Mary Hospital, Hong Kong, Caritas Medical Centre, Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, United Christian Hospital | Hip Fractures, Pneumonia | 05/25 | 06/25 | | |
ChiCTR2000031557: Comparison of efficacy and safety of denosumab versus zoledronic acid in adjuvant therapy in patients with bone metastasis: a multi-center randomized controlled trial |
|
|
| Not yet recruiting | 4 | 200 | | zoledronic acid ;denosumab | Shanghai Changzheng Hospital; Shanghai Changzheng Hospital, Grants for Scientific Research | Bone metastasis | | | | |
| Recruiting | 4 | 200 | | Alendronate sodium treatment was 70mg/ time, once a week oral. Zoledronic acid was given 5mg/ time intravenously, only once in 12 months; Desomumab, 60mg/ time, subcutaneous injection every 6 months in the abdomen.; Alendronate sodium treatment was 70mg/ time, once a week oral. Zoledronic acid was given 5mg/ time intravenously, only once in 12 months; Desomumab, 60mg/ time, subcutaneous injection every 6 months in the abdomen. | Tongji Hospital, Tongji University School of Medicine; Tongji Hospital, Tongji University School of Medicine, Self-raised funds | Type 2 diabetes mellitus and osteoprosis | | | | |
| Active, not recruiting | 4 | 20 | US | Denosumab, Zoledronic Acid, Denosumab Placebo, Zoledronic Acid Placebo | Nami Safai Haeri, The Claude D. Pepper Older Americans Independence Centers, National Institute on Aging (NIA) | Sarcopenia, Osteoporosis | 07/25 | 07/26 | | |
ChiCTR2000034931: A randomized control trial for zoledronic acid treatment in adult necrosis of femoral head |
|
|
| Recruiting | 4 | 348 | | zoledronic acid and basic treatment (drilling decompression, aspirin, calcitriol, celecoxib) ;basic treatment | West China Hospital o f Sichuan University; West China Hospital of Sichuan University, no funding | necrosis of femoral head | | | | |
NCT05493267: A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB |
|
|
| Recruiting | 4 | 30 | RoW | Vγ2Vδ2 T lymphocyte-based immunotherapy, Drug combination (zoledronic acid/interleukin 2), Treatment regimens for MDR-TB, Treatment regimen for MDR-TB using WHO guidelines | Shanghai Pulmonary Hospital, Shanghai, China, Shanghai Public Health Clinical Center, Huashan Hospital, No.85 Hospital, Changning, Shanghai, China | MDR-TB, Immunotherapy | 08/25 | 08/27 | | |
NCT05091099: The Optimal Sequential Therapy After Long Term Denosumab Treatment |
|
|
| Recruiting | 4 | 44 | RoW | Alendronate, Zoledronic acid | National Taiwan University Hospital | Osteoporosis | 12/25 | 12/25 | | |
| Recruiting | 4 | 300 | Europe | Zoledronic Acid 5Mg/Bag 100Ml Inj, Zoledronate, Aclasta, sodium chloride, NaCl | Lene Bergendal Solberg, Vestre Viken Hospital Trust, Roche Diagnostics, Diakonhjemmet Hospital | Hip Fractures, Osteoporosis | 03/26 | 03/26 | | |
ChiCTR2200066151: A study to evaluate the efficacy and safety of denosumab versus zoledronic acid in the treatment of osteopenia or osteoporosis in early breast cancer patients with aromatase inhibitors |
|
|
| Not yet recruiting | 4 | 480 | | Denosumab 60mg SC / 6 months ;Zoledronic acid 5mg IV / 12months | The First Hospital of China Medical University; The First Hospital of China Medical University, Self-financing | Osteoporosis | | | | |
| Recruiting | 4 | 3500 | US | Zoledronic Acid 5Mg/Bag 100Ml Inj, Reclast, Placebo | California Pacific Medical Center Research Institute, National Institute on Aging (NIA), University of California, San Francisco, Duke University, University of Pittsburgh, Parkinson's Foundation | Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism, Atypical Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Vascular Parkinsonism, Dementia with Lewy Bodies | 02/26 | 10/26 | | |
| Recruiting | 4 | 270 | Europe | Romosozumab, Evenity, Zoledronate | University of Aarhus | Osteoporosis | 08/26 | 08/26 | | |
NCT05091086: The Optimal Long Term Treatment Strategy of Anti-resorptive Medications---The Extension of Denosumab Sequential Therapy |
|
|
| Recruiting | 4 | 60 | RoW | Denosumab, Zoledronic acid | National Taiwan University Hospital | Osteoporosis, Bone Mineral Density | 12/26 | 12/30 | | |
NCT06118905: Preserving Geriatric Muscle With an Osteoporosis Medication |
|
|
| Recruiting | 4 | 248 | US | Denosumab 60 MG/ML, Prolia, Zoledronic Acid 5Mg/Bag 100Ml Infusion, Reclast | Susan L. Greenspan | Osteoporosis | 04/27 | 04/28 | | |
| Recruiting | 4 | 200 | US | Romosozumab, Evenity, Placebo, Zoledronic acid, Reclast, Calcium and Vitamin D | Susan L. Greenspan, National Institutes of Health (NIH), National Institute on Aging (NIA) | Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Fracture | 09/27 | 09/27 | | |
20190036, ChiCTR2400079411: A two-stage, prospective observational study describing the use and effectiveness of XGEVA/ANJIAWEI for the prevention of skeletal related events in patients with bone metastases from solid tumors rel |
|
|
| Not yet recruiting | 4 | 1000 | | XGEVA/ANJIAWE; ZOMETA | Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, Amgen Inc. | Patients with bone metastases from solid tumors (breast, prostate or lung cancer) | | | | |
ChiCTR1900022821: Multi-Center Prospective Study for Effect of Bisphosphonate in the Prevention and Treatment of Aseptic Loosening after Total Hip Arthroplasty |
|
|
| Recruiting | 4 | 702 | | Normal bone mass group 1 giving calcium carbonate D3 tablets (600 mg/day, oral), and alendronate sodium D3 tablets (1 tablet/week, oral) for 2 years versus Normal bone mass group 2: no intervention ;Osteoporosis group 1 giving Zoledronic acid: calcium carbonate D3 tablets (600 mg / day, oral), calcitriol capsules (0.25 ug / day, oral), zoledronic acid injection (5 mg intravenous drip, once a year) at least 3 year versus Osteoporosis group 2 giving Alendronate: calcium carbonate D3 tablets (600mg / day, | Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University, Sun Yat-sen Memorial Hospital of Sun Yat-sen University | Aseptic loosening of artificial joint | | | | |
2008-005667-34: A research study to determine if a drug called Zoledronic Acid prevents a serious bone disease (Paget's disease) in people who are known to have a change in a gene which has been linked to the disease. |
|
|
| Ongoing | 3/4 | 870 | Europe | Zoledronic Acid (Aclasta), Solution for infusion, Aclasta | University of Edinburgh, NHS Lothian, AZIENDA OSPEDALIERA SENESE, Medical Research Council, Arthritis UK, Arthritis Research UK, Universita, degli Studi di Edimburgo, Dpt. of Rheumatology, Molacular Medicine Centre, Prof. Stuard Ralston | Paget's disease of the bone (PDB), Paget's disease of bone (PDB) is a serious bone disease, which causes pain, arthirtis and deafness and can lead to softening of the bones causing them to enlarge and become bent., Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
ACTRN12606000293561: AZURE BR 2-03 - Adjuvant Zoledronic acid in patients with high risk localised breast cancer. |
|
|
| Active, not recruiting | 3 | 3300 | | | Prof Robert Coleman, The University of Sheffield, United Kingdom, Various cancer charities, Novartis | High risk, localised breast cancer | | | | |
| Recruiting | 3 | 100 | | | Northern Sydney Local Health District - Royal North Shore Hospital, University of Sydney Musculoskeletal, Bone & Joint Health Alliance, Department of Endocrinology, Royal North Shore Hospital | Osteoporosis, Spinal Cord Injury (SCI) | | | | |
ACTRN12607000382471: A multicentre randomised phase III study of low-dose thalidomide, prednisolone and zoledronic acid versus prednisolone and zoledronic acid for post-autologous stem cell transplant (ASCT) maintenance therapy in patients with multiple myeloma (MM6) |
|
|
| Completed | 3 | 250 | | | Australasian Leukaemia and Lymphoma Group, Amgen, Schering Plough, Pharmion | Multiple Myeloma | | | | |
NCT00698308: Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases |
|
|
| Recruiting | 3 | 680 | US | zoledronic acid, zometa, placebo | University of Medicine and Dentistry New Jersey, National Cancer Institute (NCI), Cancer and Leukemia Group B | Metastatic Cancer, Prostate Cancer | 01/08 | | | |
2011-000745-21: An international, multicenter, efficacy and safety trial of intravenous zoledronic acid in infants less than one year of age, with severe osteogenesis imperfecta Une étude clinique multicentrique sur d'efficacité et la sécurité de l'acide zoledronique intraveineux chez les nourrissons de moins d'un an atteints d'une ostéogénèse imparfaite sévère. |
|
|
| Ongoing | 3 | 15 | Europe | zoledronic acid, Solution for infusion, ACLASTA | Schriners Hospitals for Children, Shriners Hospital for Children McGill Montreal, Novartis Pharma Canana Inc. | Children suffering from severe Osteogenesis Imperfecta, Children suffering from severe Osteogenesis Imperfecta, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
| Active, not recruiting | 3 | 318 | Europe | cisplatin, doxorubicin hydrochloride, etoposide, ifosfamide, methotrexate, zoledronic acid, conventional surgery | UNICANCER, Novartis, Chugai Pharmaceutical, National Cancer Institute, France, SFCE, Ligue contre le cancer, France | Sarcoma | 12/15 | 12/26 | | |
2004-000608-42: A randomised study to determine whether zoledronic acid adds to the benefits of chemotherapy and/or hormone therapy in the treatment of women with breast cancer. –AZURE STUDY– |
|
|
| Ongoing | 3 | 120 | Europe | ZOMETA, None, ZOMETA, ZOMETA | University of Sheffield | Stage II/III primary breast cancer, with T stage ≥ T1 | | | | |
2006-003854-33: A multi-centre, randomised studyof Zoledronic Acid versus Observationin Patients with Asymptomatic Myeloma |
|
|
| Ongoing | 3 | 280 | Europe | ZOMETA*IV 1FL 4MG+1F 5ML SOLV, ZOMETA*IV 1FL 4MG+1F 5ML SOLV | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | Newly diagnosed asymptomatic MM | | | | |
2012-002107-17: International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing\'s Sarcoma Family of Tumours |
|
|
| Ongoing | 3 | 300 | Europe | Vincristine, Ifosfamide, Doxorubicin, Etoposide, Actinomycin D, Cyclophosphamide, Zoledronic acid, Vincristine Sulphate, Ifosfamide, Doxorubicin hydrochloride, Eposin, Cosmegen Lyovac, Cyclophosphamide, Zometa, Vincristine Sulphate, Ifosfamide, Doxorubicin hydrochloride, Eposin, Cosmegen Lyovac, Cyclophosphamide, Zometa | University of Birmingham, CTAAC, FP7 | Ewing\'s Sarcoma Family of Tumours | | | | |
NCT02595138: Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer |
|
|
| Active, not recruiting | 3 | 430 | RoW | Zoledronic acid | Chinese Academy of Medical Sciences, Beijing Municipal Science & Technology Commission | Triple Negative Breast Cancer | 10/18 | 12/23 | | |
2015-001527-22: CREATE-1 Study: CRPS Treatment Evaluation 1 Study. A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate) Administered Orally to Subjects with Complex Regional Pain Syndrome Type I (CRPS-I) |
|
|
| Not yet recruiting | 3 | 190 | Europe | Disodium Zoledronate Tetrahydrate, AXS-02, Tablet | Axsome Therapeutics, Inc., Axsome Therapeutics, Inc. | Complex regional pain syndrome (CRPS-I)., Severe pain in a limb accompanied by autonomic, sensory, motor and trophic changes, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] | | | | |
2019-001209-26: Multicentre, randomized, controlled, open-label, multi-centre medico-economic study evaluating the efficacy of adding zoledronic acid to Stereotaxic radiotherapy in the treatment of vertebral metastases Etude médico-économique multicentrique de phase III, randomisée, contrôlée, en ouvert, évaluant l’efficacité de l’ajout de l’acide ZOlédronique à la radiothérapie STERéotaxique dans le traitement des métastases vertébrales |
|
|
| Not yet recruiting | 3 | 225 | Europe | Injection, acide zolédronique | INSTITUT DE CANCEROLOGIE DE L'OUEST, DGOS INCa PRME17-0118 | Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy. Patients, homme ou femme âgés de plus de 18 ans et présentant des métastases vertébrales osseuses inopérables justifiant un traitement par radiothérapie stéréotaxique., Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy. Patients, homme ou femme âgés de plus de 18 ans et présentant des métastases vertébrales osseuses inopérables justifiant un traitement par radiothérapie stéréotaxique., Diseases [C] - Cancer [C04] | | | | |
2019-000757-31: A RANDOMIZED PLACEBO CONTROLLED TRIAL TESTING THE EFFECTS OF ZOLEDRONIC ACID ON HIP OSTEOARTHRITIS En randomisert placebo kontrollert studie som tester effekten av zoledronsyre på slitasjegikt i hofte |
|
|
| Not yet recruiting | 3 | 70 | Europe | Zoledronic Acid, Infusion, Zoledronic Acid (Fresenius Kabi) | Martina Hansens Hospital, South east health region Norway | Investigated disease is osteoarthritis of the hip with concurrent Bone marrow lesions Undersøkelse av pasienter med hofteartrose og sammenfallende benmargslesjoner, investigation of patients with hip osteoarthrits and bone marrow oedema on MRI Undersøkelse av pasienter med hofteslitasje og benmargsforandringer på MR, Body processes [G] - Physiological processes [G07] | | | | |
| Recruiting | 3 | 100 | RoW | Denosumab 60 mg/ml [Prolia], Denosumab 6 month/subcutaneous, Zoledronate, Zoledronic acid | Shenzhen People's Hospital | Osteopenia, Lumbar Spondylolisthesis | 02/23 | 02/23 | | |
NCT04303026: The Effect of Zoledronic Acid on Patients With Osteoarthritis of the Hip |
|
|
| Recruiting | 3 | 70 | Europe | Zoledronic Acid, Active Treatment, Saline 0.9%, Placebo | Martina Hansen's Hospital, Hormone Laboratory, Aker University Hospital, Oslo, Norway, University of Oslo | Osteoarthritis, Hip | 06/23 | 06/24 | | |
NCT05164952: Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole |
|
|
| Recruiting | 3 | 50 | RoW | Zoledronic Acid 4 MG, Zometa | Assiut University | Use of Zoledronic Acid in Breast Cancer | 08/23 | 09/23 | | |
ZOSTER, NCT03951493: Multicentre Medical-economic Study Evaluating the Efficacy of Adding ZOlédronique Acid to STERéotaxique Radiotherapy in the Treatment of Vertebral Metastases |
|
|
| Recruiting | 3 | 225 | Europe | Zoledronic Acid 4Mg Solution for Injection + Hypo-fractured radiotherapy in stereotactic conditions, Hypo-fractured radiotherapy in stereotactic conditions | Institut Cancerologie de l'Ouest | Vertebral Metastasis | 11/23 | 11/23 | | |
JMT103-012, NCT06221072: A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid |
|
|
| Not yet recruiting | 3 | 1360 | NA | JMT103, zoledronic acid | Shanghai JMT-Bio Inc. | Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors | 05/27 | 05/28 | | |
